Aromatase inhibitors in breast cancer: Current and evolving roles

John Hill, MD
Department of Hematology and Medical Oncology, The ClevelandClinic

Halle Moore, MD
Associate Professor, Department of Hematology and Clinical Oncology, The Cleveland Clinic

Address: Halle Moore, MD, Department of Hematology and Medical Oncology, R35, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail mooreh1@ccf.org

This paper discusses treatments that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

John Hill, MD
Department of Hematology and Medical Oncology, The ClevelandClinic

Halle Moore, MD
Associate Professor, Department of Hematology and Clinical Oncology, The Cleveland Clinic

Address: Halle Moore, MD, Department of Hematology and Medical Oncology, R35, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail mooreh1@ccf.org

This paper discusses treatments that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

John Hill, MD
Department of Hematology and Medical Oncology, The ClevelandClinic

Halle Moore, MD
Associate Professor, Department of Hematology and Clinical Oncology, The Cleveland Clinic

Address: Halle Moore, MD, Department of Hematology and Medical Oncology, R35, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail mooreh1@ccf.org

This paper discusses treatments that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.